Please assess the completion status of the following clinical trial:

Trial Title: Intraoperative Imaging of Pulmonary Nodules by SGM-101

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects over 18 years of age~* Subjects presenting with a lung, pleural nodule or mass presumed to be resectable on pre-operative assessment~* Good operative candidate~* Subject is capable of giving informed consent and participating in the process of consent.~Exclusion Criteria:~* At-risk subject populations:~  1. Homeless subjects~ 2. Subjects with drug or alcohol dependence~ 3. Children and neonates~ 4. Subjects unable to participate in the consent process.~* Female patients should not be pregnant or lactating. Women of child-bearing potential will be included provided that they have a negative pregnancy test or provide documentation of sterilization, menopausal or post-menopausal status, prior to infusion.~* Patients who have received SGM-101 in the past.~* Patients who have received any investigational drug four weeks of the injection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGM-101 (Type: EXPERIMENTAL): SGM-101 (5-10 mg) will be administered intravenously over 30 minutes followed by a 50 mL flush of isotonic saline to account for the dead volume of the tubing. SGM-101 will be administered 3 to 5 days (+/-1 day) prior to surgery. As a prophylactic measure to ensure the possibility of allergic reaction is absolutely minimized, 25 mg of IV Benadryl may be given the subject prior to the infusion of SGM-101 at the discretion of the Principal Investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).